Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma

M. T. Shokravi, D. M. Marcus, J. Alroy, K. Egan, M. A. Saornil, Daniel Albert

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Purpose. Vitamin D compounds have been shown to inhibit tumor growth in a transgenic retinoblastoma murine model. The mechanism of action has not been defined clearly, although an antiangiogenic action has been proposed. Methods. Transgenic retinoblastoma mice received high (0.05 μg) and low (0.025 μg) doses of vitamin D3 by intraperitoneal injection 5 times per week for 5 weeks. Control animals were injected with mineral oil vehicle alone. At 5 months of age, the animals were killed and eyes were enucleated and processed for light microscopy. Paraffin-embedded sections were stained with an immunoperoxidase stain (GS-1) specific for mammalian vascular endothelium. Sections were graded by a single masked reviewer, and intraobserver reliability was assessed. Mean vessel counts were made for each group. Results. The high-dose group had the lowest mean vessel count (8.5), followed by the low-dose group (10.1). The control group had the highest mean vessel count (14.1). Vitamin D-treated animals (high- and low-dose groups combined) had significantly fewer vessels (P = 0.001) than untreated controls. Conclusions. These results support the hypothesis that inhibition of angiogenesis is a mechanism of action for vitamin D in the transgenic retinoblastoma mouse model.

Original languageEnglish (US)
Pages (from-to)83-87
Number of pages5
JournalInvestigative Ophthalmology and Visual Science
Volume36
Issue number1
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Retinoblastoma
Vitamin D
Transgenic Mice
Mineral Oil
Cholecalciferol
Vascular Endothelium
Intraperitoneal Injections
Paraffin
Microscopy
Coloring Agents
Light
Control Groups
Growth
Neoplasms

Keywords

  • angiogenesis
  • retinoblastoma
  • transgenic mice
  • vitamin D3 compounds

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Shokravi, M. T., Marcus, D. M., Alroy, J., Egan, K., Saornil, M. A., & Albert, D. (1995). Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Investigative Ophthalmology and Visual Science, 36(1), 83-87.

Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. / Shokravi, M. T.; Marcus, D. M.; Alroy, J.; Egan, K.; Saornil, M. A.; Albert, Daniel.

In: Investigative Ophthalmology and Visual Science, Vol. 36, No. 1, 01.01.1995, p. 83-87.

Research output: Contribution to journalArticle

Shokravi, MT, Marcus, DM, Alroy, J, Egan, K, Saornil, MA & Albert, D 1995, 'Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma', Investigative Ophthalmology and Visual Science, vol. 36, no. 1, pp. 83-87.
Shokravi, M. T. ; Marcus, D. M. ; Alroy, J. ; Egan, K. ; Saornil, M. A. ; Albert, Daniel. / Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. In: Investigative Ophthalmology and Visual Science. 1995 ; Vol. 36, No. 1. pp. 83-87.
@article{33fa6c425aaa40fc8d42dd64dc01939f,
title = "Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma",
abstract = "Purpose. Vitamin D compounds have been shown to inhibit tumor growth in a transgenic retinoblastoma murine model. The mechanism of action has not been defined clearly, although an antiangiogenic action has been proposed. Methods. Transgenic retinoblastoma mice received high (0.05 μg) and low (0.025 μg) doses of vitamin D3 by intraperitoneal injection 5 times per week for 5 weeks. Control animals were injected with mineral oil vehicle alone. At 5 months of age, the animals were killed and eyes were enucleated and processed for light microscopy. Paraffin-embedded sections were stained with an immunoperoxidase stain (GS-1) specific for mammalian vascular endothelium. Sections were graded by a single masked reviewer, and intraobserver reliability was assessed. Mean vessel counts were made for each group. Results. The high-dose group had the lowest mean vessel count (8.5), followed by the low-dose group (10.1). The control group had the highest mean vessel count (14.1). Vitamin D-treated animals (high- and low-dose groups combined) had significantly fewer vessels (P = 0.001) than untreated controls. Conclusions. These results support the hypothesis that inhibition of angiogenesis is a mechanism of action for vitamin D in the transgenic retinoblastoma mouse model.",
keywords = "angiogenesis, retinoblastoma, transgenic mice, vitamin D3 compounds",
author = "Shokravi, {M. T.} and Marcus, {D. M.} and J. Alroy and K. Egan and Saornil, {M. A.} and Daniel Albert",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "36",
pages = "83--87",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "1",

}

TY - JOUR

T1 - Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma

AU - Shokravi, M. T.

AU - Marcus, D. M.

AU - Alroy, J.

AU - Egan, K.

AU - Saornil, M. A.

AU - Albert, Daniel

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Purpose. Vitamin D compounds have been shown to inhibit tumor growth in a transgenic retinoblastoma murine model. The mechanism of action has not been defined clearly, although an antiangiogenic action has been proposed. Methods. Transgenic retinoblastoma mice received high (0.05 μg) and low (0.025 μg) doses of vitamin D3 by intraperitoneal injection 5 times per week for 5 weeks. Control animals were injected with mineral oil vehicle alone. At 5 months of age, the animals were killed and eyes were enucleated and processed for light microscopy. Paraffin-embedded sections were stained with an immunoperoxidase stain (GS-1) specific for mammalian vascular endothelium. Sections were graded by a single masked reviewer, and intraobserver reliability was assessed. Mean vessel counts were made for each group. Results. The high-dose group had the lowest mean vessel count (8.5), followed by the low-dose group (10.1). The control group had the highest mean vessel count (14.1). Vitamin D-treated animals (high- and low-dose groups combined) had significantly fewer vessels (P = 0.001) than untreated controls. Conclusions. These results support the hypothesis that inhibition of angiogenesis is a mechanism of action for vitamin D in the transgenic retinoblastoma mouse model.

AB - Purpose. Vitamin D compounds have been shown to inhibit tumor growth in a transgenic retinoblastoma murine model. The mechanism of action has not been defined clearly, although an antiangiogenic action has been proposed. Methods. Transgenic retinoblastoma mice received high (0.05 μg) and low (0.025 μg) doses of vitamin D3 by intraperitoneal injection 5 times per week for 5 weeks. Control animals were injected with mineral oil vehicle alone. At 5 months of age, the animals were killed and eyes were enucleated and processed for light microscopy. Paraffin-embedded sections were stained with an immunoperoxidase stain (GS-1) specific for mammalian vascular endothelium. Sections were graded by a single masked reviewer, and intraobserver reliability was assessed. Mean vessel counts were made for each group. Results. The high-dose group had the lowest mean vessel count (8.5), followed by the low-dose group (10.1). The control group had the highest mean vessel count (14.1). Vitamin D-treated animals (high- and low-dose groups combined) had significantly fewer vessels (P = 0.001) than untreated controls. Conclusions. These results support the hypothesis that inhibition of angiogenesis is a mechanism of action for vitamin D in the transgenic retinoblastoma mouse model.

KW - angiogenesis

KW - retinoblastoma

KW - transgenic mice

KW - vitamin D3 compounds

UR - http://www.scopus.com/inward/record.url?scp=0028796340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028796340&partnerID=8YFLogxK

M3 - Article

C2 - 7529753

AN - SCOPUS:0028796340

VL - 36

SP - 83

EP - 87

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 1

ER -